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Abstract
Increasing the volume, strengthening the quality, and proactively using data of human 
immunodeficiency virus (HIV) load testing are pivotal to limiting the threat of HIV drug resistance 
(HIVDR) accumulation, and allow for optimal case-based HIVDR surveillance. Triangulation of 
viral load (VL) and HIVDR testing data could be pursued to answer key questions and translate 
data and results for program and public policy. Identification of virologic failure and early 
management mitigates the greater risk of HIVDR. Routine VL monitoring and evaluation systems 
are necessary, and countries should consider reviewing system requirements, structural needs, and 
procedural and technical factors for the entire VL cascade, with special emphasis on post-test 
result use.
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Through adoption of a public health approach, access to antiretroviral therapy (ART) in 
resource-constrained settings (RCSs) has dramatically improved, with 19.5 million people 
living with HIV receiving ART globally in 2016 [1], an increase from 7.5 million in 2010 
[2]. Key enablers of successful expansion have been the use of standardized nonnucleoside 
reverse-transcriptase inhibitor (NNRTI)–based ART regimens [3] and limited laboratory 
monitoring of the ART response. Programs in RCSs have traditionally relied on either CD4 
counts (immunologic criteria) or clinical criteria to determine patient response to ART, both 
of which are recognized as poorly predictive of ART failure [4, 5]. This evidence prompted 
the 2013 World Health Organization (WHO) guidelines to recommend routine viral load 
monitoring (VLM) for detection of treatment failure in patients on ART in RCSs [6].
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The limited use of VLM and subsequent continued exposure to failing ART and prolonged 
viremia may lead to an accumulation of drug resistance mutations (DRMs) and higher rates 
of immunosuppression and mortality [3, 7–9]. Additional negative consequences of 
virologic failure (VF) include the higher probability of transmission and potential 
transmission of resistant viruses with subsequent limited efficacy of first-line ART [10]. 
Timely detection of treatment failure is critical to individual clinical outcomes, preservation 
of second-line treatment options, and lower rates of mortality [8, 9]. Efforts to expand viral 
load (VL) testing to allow for routine and not targeted VLM are underway, facilitated by 
recent technological advances that allow simplification and decentralization of specimen 
transport and processing, such as the use of dried blood spots (DBSs) for VL quantification 
[11, 12].
Although DBS use expands access to VL testing, it does not reliably quantify viremia at 
<1000 copies/mL. Viral load studies from high-income countries have shown that patients 
with low-level viremia (LLV, commonly defined as VL between 50 and 1000 copies/mL) 
[13] harbor DRMs that confer resistance to the current ART regimen, which ultimately leads 
to treatment failure and decreases future therapeutic options [14–16]. There are limited data 
on the prevalence of LLV in RCSs [17]. A study of 1 cohort from South Africa found LLV 
in 12% of patients per year, where 27% of patients with LLV accounted for 39% of VF [18]. 
Given the potential for increased risk for VF of first-line ART in the setting of higher VL 
and longer duration of LLV, whether VF thresholds should be lowered in patients on ART in 
resource-limited settings is yet to be determined.
Expansion of VL testing in RCSs has the potential for major impact on both the emergence 
and monitoring of human immunodeficiency virus (HIV) drug resistance (HIVDR), an issue 
of particular concern in RCSs given the widespread use NNRTIs, which have a low genetic 
barrier to resistance [3]. Other factors contributing to the selection and transmission of 
HIVDR include treatment interruptions secondary to poor adherence, interruption of ARV 
commodities supply, drug–drug interactions, and delayed switching to second-line ART in 
the setting of VF [19]. Viral load suppression (VLS) confirmation may prevent DRM 
development and trigger enhanced adherence counseling and subsequent switch to a second-
line protease inhibitor–based regimen [20, 21].
In RCSs, the efficacy of national HIV treatment programs can be compromised by the 
emergence and spread of HIVDR [22]. Models have revealed significant impact of HIVDR 
on estimated AIDS deaths, HIV incidence, and ART program costs [10]. Pretreatment 
HIVDR (PDR), even at relatively low levels, has been linked with additional burden of new 
AIDS deaths and additional costs [23]. Assessment of patient-level HIVDR through 
individual genotypes is not feasible in RCS due to high cost, low throughput, and lack of 
adequate laboratory infrastructure; therefore, HIVDR monitoring in these settings has relied 
on national-level surveillance. Countries have been encouraged to develop coordinated and 
resourced national strategies to prevent, monitor, and respond to HIVDR [24]. Cross-
sectional acquired drug resistance (ADR) surveillance surveys have been proxies for 
national viral suppression and have highlighted the high rates of ADR in people failing first-
line ART, high rates of VF and ADR in children and pregnant women on ART, and 
increasing rates of PDR in some countries with more mature ART programs [25].
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AVAILABLE DATA TO MEASURE THE STATE OF VIRAL LOAD MONITORING 
EXPANSION
With expansion of VLM, routine programmatic data may serve as another source for 
estimating national and program-specific VLS. Several key stakeholders in the HIV/AIDS 
response have developed indicators to track VLS among persons living with HIV (PLHIV) 
on ART using VL tests conducted for clinical monitoring. However, in RCSs where routine 
VLM testing expansion is underway, the analysis, utilization, and generalizability of the data 
may be limited due to variability in national VL testing guidelines, VL testing coverage, data 
collection, patient tracking systems, and frequency of reporting.
Review of VL indicators from the President’s Emergency Plan for AIDS Relief (PEPFAR) 
and WHO highlight some key differences [26–28]. WHO has tackled some of the challenges 
in generalizing VLS by creating an individual indicator for VL coverage (VLS.2) among 
PLHIV newly initiated on ART and another indicator (VLS.4) to assess VL coverage among 
all PLHIV on ART. Alternatively, PEPFAR has developed an indicator (TX_PVLS) that 
determines VLS among all PLHIV on ART receiving VL testing, tracks scale-up of routine 
VLM, and may serve as a proxy for programmatic VL coverage when compared with a 
PEPFAR treatment coverage indicator (all PLHIV on ART). Both organizations primarily 
rely on patient records or ART registers as data sources, with laboratory data as an 
alternative source. Viral load testing data from laboratory information management systems 
can be extracted and deduplicated to account for multiple tests for a subset of patients. 
Application of this method has had variable success [29]. This process is also hampered by 
poor data quality and by the absence of electronic medical records (EMRs) or unique patient 
identifiers.
Challenges with collecting and interpreting VL data reported by countries include variable 
capture and accuracy of demographic and other key variables in the VL requisition form and 
limited and nonstandardized capture of VL test dates and results in clinic records in systems 
that are not electronically searchable. Even with novel adjustments in data collection, the 
challenges of interpreting and extrapolating findings to PLHIV on ART remain. To estimate 
VL coverage using routine programmatic data, other data elements are required (eg, number 
of patients eligible for and receiving VL testing). To account for the impact of variable VL 
testing guidelines, the PEPFAR indicator defines patients eligible for VL testing as those on 
ART for at least 6 months. The WHO cross-sectional VL indicator (VLS.4) does not account 
for the proportion of all PLHIV on ART eligible for VL testing. Although indicators from 
both organizations assume that VL test results recorded in the patient chart or EMR are 
proxies for VL tests performed, this may not be the case.
In 2015, the South African National Health Laboratory Services (NHLS) and others 
estimated VL coverage and suppression by deduplicating laboratory test data [29]. They 
demonstrated a significant difference between estimates of VL coverage using the national 
patient EMR (Tier.net) versus the NHLS deduplication algorithm (46% vs 75%) and striking 
variability in rates of VLS by age, sex, and geography—20% of individuals aged 15–24 
years had VL >10 000 copies/mL; in 3 provinces, VLS was ≤75%; and in 200 clinics among 
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patients receiving a VL test, VLS was <50%. Findings from the NHLS deduplicated dataset 
emphasize the need for integrated data health systems that allow for subpopulation analyses.
HARNESSING THE DATA
In recently completed population-based HIV impact assessments in Zambia, Zimbabwe, and 
Malawi, the prevalence of VLS in adult PLHIV who self-reported ART use (adults aged 15–
64 years) was 89.2%, 86.5%, and 90.8%, respectively [30]. These countries are making great 
strides toward achieving the UNAIDS 90-90-90 targets. In these 3 countries, female and 
older adult PLHIV had higher rates of VLS than male and younger adult PLHIV. Younger 
adult males (aged 15–24 years) had the lowest VLS according to these national surveys, 
which provide critical information about potential for drug-resistance development and 
public health impact.
Countries like South Africa and Mozambique have demonstrated the utility in both 
developing data systems and triangulating data from multiple sources to perform meaningful 
data analyses [29, 31]. Other studies have demonstrated the potential of mathematical 
models and algorithms applied to EMRs to optimize patient management [32].
CALL TO ACTION
Viral load and HIVDR are closely intertwined; increased VL testing and strengthening the 
quality and use of VL data can play a pivotal role in both decreasing emergence of HIVDR 
and allowing for more optimal HIVDR surveillance in the future (eg, case-based). Higher 
rates of VF serve as signals that may impact HIVDR and need to be identified and managed 
early to mitigate the risk. The expansion of routine VLM and strengthening of VLM and 
evaluation systems offer a strategic opportunity for countries to review the system 
requirements, structural needs, and procedural and technical factors for the entire VL 
cascade, with special emphasis on post-test result utilization. Overcoming limitations to VL 
expansion across the entire system (such as sample-processing backlogs; fragile systems for 
an effective and sustainable VL cascade; limited patient and provider demand; and lack of 
telecommunication infrastructure, standard procedures for returning VL results to clinical 
record systems, and proper interpretation, quality assurance, and data use) is crucial. Site-
level clinical mentoring, supportive supervision, and identification of ART program factors 
that be adjusted to minimize the emergence of VF and HIVDR and optimize treatment 
outcomes are essential and should be pursued concomitantly with HIVDR surveillance 
efforts.
To maximize utility of VL as a monitoring tool, preserve treatment options, and limit the 
threat of widespread HIVDR, scaling up routine VLM requires collaboration between 
stakeholders. The clinical, laboratory, and strategic information stakeholders should be 
convened to routinely review their current VL data collection systems (eg, forms, registers, 
lab information systems, EMR, patient databases), agree on VL data priorities, and develop 
a way forward for monitoring systems to routinely provide disaggregated VLS program data. 
Despite current limitations of available VL data, efforts to strengthen the collection, 
analysis, and utilization of data to inform and improve the quality of HIV services and 
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patient outcomes are crucial. Ongoing VL and HIVDR data triangulation efforts may answer 
key program questions and translate data and results for program and public policy. 
Collectively improving our VL and HIVDR intelligence is more critical than ever.
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